Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
First-generation bromodomain extra-terminal protein (BETP) inhibitors (BETi) (e.g., OTX015) that disrupt binding of BETP BRD4 to chromatin transcriptionally attenuate AML-relevant progrowth and prosurvival oncoproteins. BETi treatment induces apoptosis of AML BPCs, reduces in vivo AML burden and induces clinical remissions in a minority of AML patients. Clinical efficacy of more potent BETis, e.g., ABBV-075 (AbbVie, Inc.), is being evaluated. Venetoclax and A-1210477 bind and inhibit the antiapoptotic activity of BCL2 and MCL1, respectively, lowering the threshold for apoptosis. BETi treatment is shown here to perturb accessible chromatin and activity of enhancers/promoters, attenuating MYC, CDK6, MCL1 and BCL2, while inducing BIM, HEXIM1, CDKN1A expressions and apoptosis of AML cells. Treatment with venetoclax increased MCL1 protein levels, but cotreatment with ABBV-075 reduced MCL1 and Bcl-xL levels. ABBV-075 cotreatment synergistically induced apoptosis with venetoclax or A-1210477 in patient-derived, CD34+ AML cells. Compared to treatment with either agent alone, cotreatment with ABBV-075 and venetoclax was significantly more effective in reducing AML cell-burden and improving survival, without inducing toxicity, in AML-engrafted immune-depleted mice. These findings highlight the basis of superior activity and support interrogation of clinical efficacy and safety of cotreatment with BETi and BCL2 or MCL1 inhibitor in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, their effectiveness in acute myeloid leukemia (AML) is limited by compensatory MCL-1 accumulation via the ubiquitin proteasome system.”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [29]
In the citing paper
“For example, venetoclax induces MCL-1 up-regulation in AML cells,29”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [29]
In the citing paper
“Several studies have demonstrated that B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3)-mimetics induce MCL-1 up-regulation as a compensatory response in leukemia cells.”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [29]
In the citing paper
“However, such BH3-mimetics, as well as others targeting alternative BCL-2 family proteins e.g., BCL-2 and BCL-xL, elicit a rebound up-regulation of these proteins,29 thereby attenuating anti-apoptotic activities.”
From Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia (2025) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers
Hnisz, D., Schuijers, J., Lin, C. Y., Weintraub, A. S., Abraham, B. J., Lee, T. I., Bradner, J. E., & Young, R. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.014 · Cited by 476
Winter, G. E., Mayer, A., Buckley, D. L., Erb, M. A., Roderick, J. E., Vittori, S., Reyes, J. M., di Iulio, J., Souza, A., Ott, C. J., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.004 · Cited by 465
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
Pan, R., Ruvolo, V., Mu, H., Leverson, J. D., Nichols, G., Reed, J. C., Konopleva, M., & Andreeff, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.003 · Cited by 300
Self-citation
Research works printed but not linked: 50
- Belkina, A. C. & Denis, G. V. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer 12, 465–477 (2012). · DOI · Paper page
- Shi, J. & Vakoc, C. R. The mechanism behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54, 728–736 (2014). · DOI · Paper page
- Itzen, F., Greifenberg, A. K., Bosken, C. A. & Geyer, M. Brd4 activates P-TEFB for RNA polymerase II CTD phosphorylation. Nucleic Acids Res. 42, 7577–7590 (2014). · DOI · Paper page
- Nechaev, S. & Adelman, K. Pol II waiting in the starting gates: regulating the transition from transcription initiation into productive elongation. Biochim. Biophys. Acta 1809, 34–45 (2011). · DOI · Paper page
- Bradner, J. E., Hnisz, D. & Young, R. A. Transcriptional addiction in cancer. Cell 168, 629–643 (2017). · DOI · Paper page
- Bhagwat, A. S., Lu, B. & Vakoc, C. R. Enhancer dysfunction in leukemia. Blood 131, 1795–1804 (2018). · DOI
- Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011). · DOI · Paper page
- Fiskus, W. et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol. Cancer Ther. 13, 1142–1154 (2014). · DOI · Paper page
- Dawson, M. A. et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 28, 311–320 (2014). · DOI · Paper page
- Berthon, C. et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 3, e186–e195 (2016). · DOI · Paper page
- Braun, T. & Gardin, C. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML). Expert Opin. Investig. Drugs 26, 803–811 (2017). · DOI · Paper page
- Filippakapoulos, P. & Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13, 337–356 (2014). · DOI · Paper page
- McDaniel, K. F. et al. Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor. J. Med. Chem. 60, 8369–8384 (2017). · DOI · Paper page
- Tanaka, M. et al. Design and characterization of bivalent BET inhibitors. Nat. Chem. Biol. 12, 1089–1096 (2016). · DOI · Paper page
- Rhyasen, G. W. et al. AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies. Mol. Cancer Ther. 15, 2563–2574 (2016). · DOI · Paper page
- Hogg, S. J. et al. BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members. Mol. Cancer Ther. 15, 2030–2041 (2016). · DOI · Paper page
- Adams, J. M. & Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324–1337 (2007). · DOI · Paper page
- Dai, H., Meng, X. W. & Kaufmann, S. H. Mitochondrial apoptosis and BH3 mimetics. F1000Res. 5, 2804–2815 (2016). · DOI
- Leverson, J. D. et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov. 7, 1376–1393 (2017). · DOI · Paper page
- Pan, R. et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4, 362–375 (2014). · DOI · Paper page
- Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013). · DOI · Paper page
- Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106–1117 (2016). · DOI · Paper page
- Tahir, S. K. et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. Bmc Cancer 17, 399 (2017). · DOI · Paper page
- Teh, T. C. et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia 32, 303–312 (2018). · DOI · Paper page
- Phillips, D. C. et al. Loss in MCL1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 5, e368 (2015). · DOI
- Bogenberger, J. M. et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 28, 1657–1665 (2014). · DOI · Paper page
- DiNardo, C. D. et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am. J. Hematol. 93, 401–407 (2018). · DOI · Paper page
- Soderquist, S., Eastman, R. & A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol. Cancer Ther. 15, 2011–2017 (2016). · DOI
- Valentin, R., Grabow, S. & Davids, M. S. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood 132, 1248–1264 (2018). · DOI · Paper page
- Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351–365 (2006). · DOI · Paper page
- Vo, T. T. et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151, 344–355 (2012). · DOI · Paper page
- Ni Chonghaile, T. et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334, 1129–1133 (2011). · DOI · Paper page
- Rooswinkel, R. W. et al. Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. Blood 123, 2806–2815 (2014). · DOI · Paper page
- Dai, H. et al. Measurement of BH3-only protein tolerance. Cell Death Differ. 25, 282–293 (2018). · DOI
- Luedtke, D. A. et al. Inhibition of MCL1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct. Target Ther. 2, 17012 (2017). · DOI
- Lin, K. H. et al. Targeting MCL1/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci. Rep. 6, 27696 (2016). · DOI · Paper page
- Saenz, D. T. et al. BET protein bromodomain inhibitor-based combinations are highly active against postmyeloproliferative neoplasm secondary AML cells. Leukemia 31, 678–687 (2017). · DOI
- Devaraj, S. G. et al. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia 30, 504–508 (2016). · DOI
- Bui, M. H. et al. preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Res. 77, 2976–2989 (2017). · DOI
- Lin, X. et al. HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues. Mol. Cancer Ther. 16, 388–396 (2017). · DOI
- Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311–322 (2016). · DOI · Paper page
- Fresquet, V., Rieger, M., Carolis, C., García-Barchino, M. J. & Martinez-Climent, J. A. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood 123, 4111–4119 (2014). · DOI · Paper page
- Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163–3169 (2012). · DOI · Paper page
- Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488–496 (2012). · DOI · Paper page
- Zhong, Q., Gao, W., Du, F. & Wang, X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of MCL1 and regulates apoptosis. Cell 121, 1085–1095 (2005). · DOI · Paper page
- Dey, J. et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci. Rep. 7, 18007 (2017). · DOI
- Ruefli-Brasse, A. & Reed, J. C. Therapeutics targeting Bcl-2 in hematological malignancies. Biochem. J. 474, 3643–3657 (2017). · DOI
- Kojima, K. et al. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 5, 2778–2786 (2006). · DOI · Paper page
- Chan, S. M. et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat. Med. 21, 178–184 (2015). · DOI · Paper page
- Lagadinou, E. D. et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12, 329–341 (2013). · DOI · Paper page
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Emerging agents and regimens for AML
Liu, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01062-w · Cited by 289
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Carter, J. L., Hege, K., Yang, J., Kalpage, H. A., Su, Y., Edwards, H., Hüttemann, M., Taub, J. W., & Ge, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00361-x · Cited by 218
Targeting MCL-1 protein to treat cancer: opportunities and challenges
Tantawy, S. I., Timofeeva, N., Sarkar, A., & Gandhi, V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1226289 · Cited by 90
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia
Hu, X., Li, L., Nkwocha, J., Kmieciak, M., Shang, S., Cowart, L. A., Yue, Y., Horimoto, K., Hawkridge, A., Rijal, A., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02125-x · Cited by 15
Metadata
- Authors
- Fiskus, W., Cai, T., DiNardo, C. D., Kornblau, S. M., Borthakur, G., Kadia, T. M., Pemmaraju, N., Bose, P., Masarova, L., Rajapakshe, K., Perera, D., Coarfa, C., Mill, C. P., Saenz, D. T., Saenz, D. N., Sun, B., Khoury, J. D., Shen, Y., Konopleva, M., & Bhalla, K. N.
- Venue
- Blood Cancer Journal
- Published
- 2019-01-15
- Volume
- 9
- Issue
- 2
- ISSN
- 2044-5385
- Cited by
- 62
- References
- 10
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. https://app.cochat.ai/papers/10.1038/s41408-018-0165-5
- The paper
- Fiskus, W., Cai, T., DiNardo, C. D., Kornblau, S. M., Borthakur, G., Kadia, T. M., Pemmaraju, N., Bose, P., Masarova, L., Rajapakshe, K., Perera, D., Coarfa, C., Mill, C. P., Saenz, D. T., Saenz, D. N., Sun, B., Khoury, J. D., Shen, Y., Konopleva, M., & Bhalla, K. N. (2019). Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer Journal. https://doi.org/10.1038/s41408-018-0165-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.